Učitavanje...
Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial
SUMMARY: BACKGROUND: In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral density (BMD)...
Spremljeno u:
| Izdano u: | Lancet Diabetes Endocrinol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6980341/ https://ncbi.nlm.nih.gov/pubmed/31447409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(19)30255-4 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|